Cytokinetics vs Rhythm Pharmaceuticals

Cytokinetics (CYTK), health care, and Rhythm Pharmaceuticals (RYTM), health care, side by side on market value, valuation, margins, balance sheet and price change. Higher and lower are marked; neither is called better.

Rhythm Pharmaceuticals is worth $8.1B on the stock market and Cytokinetics $7.2B: Rhythm Pharmaceuticals is valued at 12% more. Cytokinetics's operating margin in its latest fiscal year was -695% and Rhythm Pharmaceuticals's -101%. Over the past year Cytokinetics's share price has moved -19.6% and Rhythm Pharmaceuticals's +6.93%.

Key facts

Cytokinetics market value
$7.2B
Rhythm Pharmaceuticals market value
$8.1B
Cytokinetics revenue
$88MFY to 2025-12-31
Rhythm Pharmaceuticals revenue
$189.8MFY to 2025-12-31
Superinvestors holding both
1

Market values as of .

Cytokinetics vs Rhythm Pharmaceuticals: every measure side by side
Measure Cytokinetics Rhythm Pharmaceuticals
SectorHealth CareHealth Care
Country United States United States
Fiscal year ends2025-12-312025-12-31
Size
Market cap$7.2Blower$8.1Bhigher
Revenue$88Mlower$189.8Mhigher
Earnings-$785Mlower-$196.5Mhigher
Employees673higher414lower
Total assets$1.4Bhigher$480.2Mlower
Valuation
P/E——
P/S81.7higher42.6lower
P/B—91.9
Dividend yield0.00%0.00%
Profitability
Operating margin-695%lower-101%higher
Balance sheet
Net assets-$659.6Mlower$139.1Mhigher
Total liabilities$2.1Bhigher$210.2Mlower
Total debt$287.6Mhigher$108.2Mlower
Cash on hand$122.5Mhigher$54.3Mlower
Price change
Today-2.86%lower+8.49%higher
1 year-19.6%lower+6.93%higher

Market value, P/E, P/B, dividend yield and price changes are from live quotes (Yahoo Finance; prices may be delayed 15 minutes or more). Revenue, earnings, operating margin and the balance-sheet figures are from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day. P/S sets today's market value against the latest fiscal year's revenue. “Higher” and “lower” compare the two numbers only; a higher P/E or more debt is not better. Dividend yield and P/B are shown only for companies based in the US. A dash means no figure is on file.

Loading the one-year price chart…

Which superinvestors hold them

From each tracked investor's latest 13F filing. A 13F lists long positions in US-listed shares at a quarter end, filed up to 45 days later.

Both (1)

Cytokinetics only (2)

Rhythm Pharmaceuticals only (3)

Percentages are each holding's share of that investor's reported portfolio (under "Both": Cytokinetics / Rhythm Pharmaceuticals). Who owns CYTK · Who owns RYTM

Further comparisons

Learn

Questions and answers

Which is bigger, Cytokinetics or Rhythm Pharmaceuticals?

By market value, Rhythm Pharmaceuticals is the larger: $8.1B against $7.2B for Cytokinetics. By revenue in its latest fiscal year, Rhythm Pharmaceuticals is the larger: $189.8M against $88M for Cytokinetics.

Which has the higher operating margin?

Rhythm Pharmaceuticals: -101%, against -695% for Cytokinetics. Operating margin is operating income as a share of revenue in the latest fiscal year.

Which has the higher dividend yield?

Neither: both stand at 0.00%. Dividend yield is the last twelve months' dividends as a share of today's share price.

Which has more debt?

Cytokinetics: $287.6M, against $108.2M for Rhythm Pharmaceuticals. Total debt is borrowings at the end of the latest fiscal year, as each company reported it; it is not set against cash here.

Which superinvestors own both Cytokinetics and Rhythm Pharmaceuticals?

In their latest 13F filings, Julian and Felix Baker holds both.

Cite this page

Funkfolio, “Cytokinetics vs Rhythm Pharmaceuticals”, data as of 17 November 2026. https://funkfolio.com/compare/cytk-vs-rytm

Underlying data: Yahoo Finance quotes; SEC annual reports collected 2026-11-12; 13F filings.